

HIGHLIGHTS

AEDV

en la 6ª edición del SPIN

Skin Inflammation & Psoriasis
International Network Congress

PARIS
25-27
abril

PSORIASIS

Marta Ferrán


Servicio de Dermatología
Hospital del Mar. Barcelona

Iniciativa científica de:




PS1. GENETICS AND IMMUNOPATHOGENESIS OF PUSTULAR VARIANTS OF PSORIASIS (H. Bachelez)

- Genetically-inherited IL-36RA structural and functional abnormalities play a major role in GPP
- IL-36RN severely impairing mutations are preferentially associated with the most severe phenotypes
- IL36RN mutations are associated with an earlier age of onset across all variants of pustular psoriasis



- *CARD14* mutations are observed in only a small minority of cases
 - *CARD14* mutations in GPP, PPP and PRP impact on NFκB and IL-36 pathways
- *AP1S3* mutations occur with comparable frequency across disease types
 - *AP1S3* mutations are associated with impaired Toll-like Receptor 3 trafficking
- Respiratory virus triggering events are involved in GPP / DITRA flares
- Results from early phase development of IL-36RA-blocking strategies are promising in GPP



FOCUS SESSION: ADVANCES IN TARGET-ORIENTED THERAPY. PSORIASIS (B. Kirby)


- Anti-IL-17A (secukinumab, ixekizumab, brodalumab)
 - Long-term efficacy data
 - Long-term safety data
 - Rapid onset of action
- Bimekizumab (anti-IL17A/F)
- Anti-p19 IL23 (guselkumab, risankizumab, tildrakizumab, mirikizumab)
 - Efficacy / safety data
 - Maintenance of PASI-90 response after withdrawal

FOCUS SESSION: ADVANCES IN TARGET-ORIENTED THERAPY. PSORIATIC ARTHRITIS (W. Boehncke)

- Anti-TNFs are still the gold standard therapy
- New therapies
 - Anti-IL-17A/F, IL-23p19
 - JAK inhibition
- Assessment might be improved through replacing ACR criteria by PSA-focused measures (MDA?)
- T2T is about to become a widely established therapeutic strategy

PO.18: ADALIMUMAB VS ADALIMUMAB +MTX IN PSORIASIS: FIRST-YEAR RESULTS ON EFFECTIVENESS, DRUG SURVIVAL, SAFETY AND IMMUNOGENECITY (G. Kraaij, Amsterdam)

- Pragmatic RCT, assessor blinded
- Adalimumab vs adalimumab (n=30) + MTX 10mg / week (n=31)
 - PASI ≥ 8 (eligible according to guidelines)
 - Adalimumab naive
 - Follow-up every 12w for 3 years: 1st year results (week 49)
- PASI-75:
31% ADA vs 58% ADA+MTX (p=0,04)
- ADA survival:
59% ADA vs 74 % ADA + MTX (p=0,26)
- Antidrug antibodies:
47% ADA vs 16% ADA + MTX (p=0,01)





GRACIAS

Iniciativa científica de:

